Clinical Trials · NCT06972472
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
- Phase
- Phase 3
- Recruitment status
- Active Not Recruiting
- Sponsor
- Eli Lilly and Company
- Enrollment
- 600
- Start date
- May 2025
- Locations
- 80 sites, 7 countries
- Primary endpoint
- Change from Baseline in Hemoglobin A1c (HbA1c)